Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totaling 8,448 shares, a drop of 83.0% from the July 15th total of 49,784 shares. Based on an average daily trading volume, of 31,236 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are short sold.
Sonoma Pharmaceuticals Stock Performance
Shares of NASDAQ SNOA traded down $0.03 during mid-day trading on Wednesday, reaching $1.34. The company’s stock had a trading volume of 38,784 shares, compared to its average volume of 137,247. The stock has a market capitalization of $6.40 million, a P/E ratio of -1.10 and a beta of 1.28. Sonoma Pharmaceuticals has a 1-year low of $0.85 and a 1-year high of $6.92. The stock has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.85.
Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.32. Sonoma Pharmaceuticals had a negative return on equity of 26.32% and a negative net margin of 10.33%.The firm had revenue of $6.41 million for the quarter, compared to the consensus estimate of $4.99 million.
Institutional Investors Weigh In On Sonoma Pharmaceuticals
Wall Street Analyst Weigh In
Separately, Weiss Ratings raised Sonoma Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Sonoma Pharmaceuticals presently has a consensus rating of “Sell”.
View Our Latest Stock Analysis on SNOA
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.
At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.
Featured Stories
- Five stocks we like better than Sonoma Pharmaceuticals
- CoreWeave’s $129 Billion AI Backlog Changes the Bull Case
- Tesla’s Robotaxi Reality Check: Time to Deliver
- Hims & Hers’ Revenue Beat Came With a Profitability Problem
- A Westinghouse IPO Could Reset the Nuclear Stock Conversation
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
